Abstract
Although infective endocarditis (IE) is not the most frequent infection seen in intravenous (IV) drug abusers (IVDAs), health care providers should always regard it as a possible diagnosis in this population. Many researchers have tried to elucidate the clinical, epidemiologic, immunologic and pathogenetic aspects of this entity. Right-sided endocarditis accounts for almost 10% of all IE episodes and has been most commonly interrelated with IV use of illicit substances. On the other hand, recent reports have proposed that left-sided valve participation is seen more often now than in the past. While, our progress in medicine, new diagnostic criteria and especially modern imaging techniques have broadened our ability to recognize IE, there are still some gray areas regarding right-sided IE. Our aim is to comprehensively review the clinical features and complications and also the possible pathogenetic and immunologic mechanisms implicated in IE patients who are injecting illicit substances.
Keywords: Infective endocarditis, drug abuse, clinical presentation, immunology, pathogenesis, unremitting fever, bacteraemia, dyspnoea, haemoptysis, conjunctival haemorrhages
Current Vascular Pharmacology
Title: Dealing with the Substance Abuse Epidemic and Infective Endocarditis:Clinical, Immunologic and Pathogenetic Aspects
Volume: 10 Issue: 2
Author(s): Ioannis Starakis, George Panos and Elias Mazokopakis
Affiliation:
Keywords: Infective endocarditis, drug abuse, clinical presentation, immunology, pathogenesis, unremitting fever, bacteraemia, dyspnoea, haemoptysis, conjunctival haemorrhages
Abstract: Although infective endocarditis (IE) is not the most frequent infection seen in intravenous (IV) drug abusers (IVDAs), health care providers should always regard it as a possible diagnosis in this population. Many researchers have tried to elucidate the clinical, epidemiologic, immunologic and pathogenetic aspects of this entity. Right-sided endocarditis accounts for almost 10% of all IE episodes and has been most commonly interrelated with IV use of illicit substances. On the other hand, recent reports have proposed that left-sided valve participation is seen more often now than in the past. While, our progress in medicine, new diagnostic criteria and especially modern imaging techniques have broadened our ability to recognize IE, there are still some gray areas regarding right-sided IE. Our aim is to comprehensively review the clinical features and complications and also the possible pathogenetic and immunologic mechanisms implicated in IE patients who are injecting illicit substances.
Export Options
About this article
Cite this article as:
Starakis Ioannis, Panos George and Mazokopakis Elias, Dealing with the Substance Abuse Epidemic and Infective Endocarditis:Clinical, Immunologic and Pathogenetic Aspects, Current Vascular Pharmacology 2012; 10 (2) . https://dx.doi.org/10.2174/157016112799304978
DOI https://dx.doi.org/10.2174/157016112799304978 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Use of Nanoparticles as Therapy for Methicillin-Resistant Staphylococcus aureus Infections
Current Drug Metabolism Thoracic Aortic Aneurysm: Blood Pressure and Inflammation as Key Factors in the Development of Aneurysm Dissection
Current Pharmaceutical Design Catastrophic Antiphospholipid Syndrome: Lessons from the “CAPS Registry”
Current Rheumatology Reviews Antithrombotic Therapy in Cardiac Embolism
Current Cardiology Reviews Proteomics Analysis: A Powerful Tool to Identify Proteome Phenotype and Proteome Signature in Enterococcus faecalis
Current Proteomics Methylene Blue and Vasoplegia: Who, When, and How?
Mini-Reviews in Medicinal Chemistry Antibacterial Combination of Oleoresin from Copaifera multijuga Hayne and Biogenic Silver Nanoparticles Towards Streptococcus agalactiae
Current Pharmaceutical Biotechnology The Evaluation and Management of Adult-Onset Henoch-Schonlein Purpura
Current Rheumatology Reviews Optimization of Drug Safety Profile in Inflammatory Bowel Disease Through a Personalized Approach
Current Drug Targets Best Practice for Atrial Fibrillation Patient Education
Current Pharmaceutical Design Inside the Pan-genome - Methods and Software Overview
Current Genomics Polyproline and Triple Helix Motifs in Host-Pathogen Recognition
Current Protein & Peptide Science The Gut Mucosa as a Site for Induction of Regulatory T-Cells
Current Pharmaceutical Design Alkaloids: An Emerging Antibacterial Modality Against Methicillin Resistant Staphylococcus aureus
Current Pharmaceutical Design Current Status of Molecular Imaging in Infections
Current Pharmaceutical Design Q Fever Endocarditis
Infectious Disorders - Drug Targets Infection and Hemodialysis Access: An Updated Review.
Infectious Disorders - Drug Targets Potential Therapeutic Application of Chondroitin Sulfate/Dermatan Sulfate
Current Drug Discovery Technologies CA125: An Increasingly Promising Biomarker of Heart Failure
Current Pharmaceutical Design Review of Airway Illnesses by Kytococcus and Rothia and a Look at Inhalatory Vancomycin as a Treatment Support
Recent Patents on Anti-Infective Drug Discovery